Through ICBcomb, in the case study on the ICB combination therapy in NSCLC, we deduced that the ICB combination therapy promotes the polarization of M2 macrophages toward the M1 type, leading to an augmented infiltration of the CD8+ T cells into tumor tissues and enhancing the therapeutic effect of anti-PD-1. The gene discussed is CD8A; the disease is neoplasm.